Rocmira Pérez-Nicado, Chiara Massa, Laura Marta Rodríguez-Noda, Anja Müller, Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, Beatriz Paredes-Moreno, Meiby Rodríguez-González, Marylé García-Ferrer, Ilianet Palmero-Álvarez, Aniurka Garcés-Hechavarría, Daniel G Rivera, Yury Valdés-Balbín, Vicente Vérez-Bencomo, Dagmar García-Rivera, Barbara Seliger
(1) Background: In children, SARS-CoV-2 infection is mostly accompanied by mild COVID-19 symptoms. However, multisystem inflammatory syndrome (MIS-C) and long-term sequelae are often severe complications. Therefore, the protection of the pediatric population against SARS-CoV-2 with effective vaccines is particularly important. Here, we compare the humoral and cellular immune responses elicited in children ( n = 15, aged 5-11 years) vaccinated with the RBD-based vaccines SOBERANA® 02 and SOBERANA® Plus combined in a heterologous scheme with those from children ( n = 10, aged 4-11 years) who recovered from mild symptomatic COVID-19...
October 25, 2023: Vaccines